<DOC>
	<DOCNO>NCT00822666</DOCNO>
	<brief_summary>To evaluate role genetic variant 2C19*2 pharmacodynamic response assess optical aggregometry pharmacokinetic response assess measure active metabolite follow oral administration load dose 300/900mg clopidogrel patient establish coronary artery disease .</brief_summary>
	<brief_title>Clopidogrel Response Variability Investigation Study 2</brief_title>
	<detailed_description>Rationale : Clopidogrel specific irreversible P2Y12 platelet receptor lead inhibition platelet aggregation . Clopidogrel prodrug must convert active metabolite selectively irreversibly bind P2Y12 platelet membrane receptor . As consequence , load dose 300 mg necessary percutaneous coronary intervention acute coronary syndrome , situation require rapid inhibition platelet aggregation due high thrombotic risk . High platelet reactivity clopidogrel may due various reason include polymorphism gene encode cytochrome P-450 2C19 enzyme ( CYP2C19 ) show contribute variability platelet response clopidogrel . CYP2C19 key enzyme activation process group first describe association presence loss function CYP2C19 681G &gt; A polymorphism ( also call *2 ) low clopidogrel responsiveness healthy subject . Poor responsiveness clopidogrel become major concern give acute recurrent event follow stent placement . Objective : To evaluate role genetic variant 2C19*2 pharmacodynamic response assess optical aggregometry pharmacokinetic response assess measure active metabolite follow oral administration load dose 300/900mg clopidogrel patient establish coronary artery disease . Target population : Patients le 45 year age survive MI enrol AFIJI multicenter registry ( Appraisal risk Factors young Ischemic patient Justifying aggressive Intervention ) . Primary end-point : Comparison inhibition intensity residual platelet aggregation ( IRPA ) measure 6 minute induction 20 μmol/L follow 300mg 900 mg clopidogrel respect presence genetic variant CYP2C19*2 1 . Maximum platelet aggregation instead IRPA 2 . RPA 5µM 50 µM ADP 3 . Measure clopidogrel active metabolite ( carboxylate thiol ) different time point follow load dose ( H0 , H1 , H2 et H6 ) respect presence genetic variant CYP2C19*2 4 . Relationship active metabolite concentration IRPA 5 . Relationship active metabolite dose clopidogrel 6 . Comparison 300mg v 900mg IRPA whole population irrespective genetic variant Statistical analysis : Comparison IRPA respect presence genetic variant 2C19*2 anova Area curve production active metabolite respect presence genetic variant 2C19*2 Agenda : November 2008 ( inclusion first patient ) december 2009 ( analysis data )</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<criteria>Age &gt; 18 Male gender Included AFIJI registry No high bleeding risk profile No recent history acute coronary syndrome ( &lt; 3 month ) Written informed consent obtain Genotype CYP2C19 : *1/*1 , *1/*2 ou *2/*2 Genotype P2Y12 : H1/H1 ou H1/H2 Female gender Patient contraindication clopidogrel Patient receive load dose clopidogrel past 7 day Patient treat ticlopidine GP2B/3A receptor antagonist prior load Non compliance Génotype P2Y12 : H2/H2 . Patient treat drug interact platelet aggregation ( NSAID , persantine , serotonin inhibitor ) Patient treat drug interact 2C19 Not affiliated national health insurance Patient participate another randomize study</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2009</verification_date>
	<keyword>Platelet aggregation</keyword>
	<keyword>Platelet</keyword>
	<keyword>Thrombosis</keyword>
	<keyword>Clopidogrel</keyword>
</DOC>